Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone‐refractory prostate carcinoma

200455 citationsJournal Article

Authors

Axel Heidenreich · University of Cologne

Frank Sommer · University of Cologne

Carsten‐Henning Ohlmann · Philipps University of Marburg

Andres Jan Schrader · Philipps University of Marburg

P. Olbert · Philipps University of Marburg

Joachim Goecke · Philipps University of Marburg

U. Engelmann

Abstract

Pegylated liposomal doxorubicin yielded a noteworthy objective palliative response rate and a mean survival of 13 months for patients with symptomatic HRPCA. The dosage tested in the current study should be used in future Phase II and Phase III trials of pegylated liposomal doxorubicin-containing combination regimens for patients with HRPCA.

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 101, Issue 5, pp. 948-956

DOI: 10.1002/cncr.20455

Field-Weighted Citation Impact: 4.92